欧洲委员会批准辉瑞Hympavzi用于治疗伴抑制物的A型或B型血友病成人与青少年

美股速递
May 13

欧洲监管机构已正式批准辉瑞公司的新药Hympavzi,用于治疗伴有抑制物的A型或B型血友病的成年患者及青少年患者。这一批准为面临传统疗法挑战的血友病人群提供了一种新的治疗选择。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10